甲状腺功能减退与小肠细菌过度生长风险及十二指肠微生物组改变的关系
研究评估甲状腺功能减退或自身免疫性甲状腺炎患者发生小肠细菌过度生长(SIBO)的风险及十二指肠微生物组变化。REIMAGINE研究中甲减组SIBO患病率高于对照组(32.65% vs 15.17%)。TriNetX分析显示甲减(RR=2.20)和自身免疫性甲状腺炎(RR=2.40)患者10年SIBO累积发病率较高,但服用左甲状腺素者风险降低。
要点
- 甲减患者SIBO患病率较对照组升高。
- 甲减及自身免疫性甲状腺炎患者10年SIBO累积发病率增加。
- 左甲状腺素治疗可能降低SIBO风险。
核心结论
- 有甲减病史的个体发生SIBO的风险增加,可能通过治疗减轻,并涉及特定革兰阴性大肠菌群。
研究设计与样本
- REIMAGINE研究纳入有甲减病史者49例和对照组323例,进行十二指肠抽吸物16S rRNA测序,部分行宏基因组测序。
- 利用TriNetX Analytics平台评估甲减(未指定病因)和自身免疫性甲状腺炎患者与倾向评分匹配对照组的10年SIBO累积发病率和相对风险(RR)。
主要发现
- REIMAGINE研究中,甲减组SIBO患病率为32.65%,对照组为15.17%。
- TriNetX分析中,甲减(未指定病因)患者10年SIBO累积发病率高于匹配对照组,RR=2.20。
- 自身免疫性甲状腺炎患者10年SIBO累积发病率高于匹配对照组,RR=2.40。
- 服用左甲状腺素的甲减(未指定病因)患者RR=0.33,自身免疫性甲状腺炎患者RR=0.78。
- 十二指肠微生物组分析显示,奈瑟菌属在甲减组(Hypo+/SIBO-和Hypo+/SIBO+)核心微生物组中,而在非甲减组(Hypo-/SIBO-和Hypo-/SIBO+)中不存在。
临床怎么用
- 对甲减患者应关注SIBO相关症状,左甲状腺素治疗可能降低SIBO风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: There is an association between hypothyroidism and small intestinal bacterial overgrowth (SIBO), but the exact mechanistic link between these 2 conditions is not fully elucidated. OBJECTIVE: We evaluate the incidence and risks of subsequently developing SIBO, and changes in small bowel microbial populations, in subjects with hypothyroidism or autoimmune thyroiditis. DESIGN AND OUTCOME MEASURES: Duodenal aspirates from REIMAGINE study subjects with a history of hypothyroidism (hypothyroid group, N = 49) and controls (N = 323) underwent 16S rRNA sequencing (MiSeq, Illumina); a subset also underwent metagenomic sequencing (NovaSeq6000, Illumina). Separately, the TriNetX Analytics platform was used to evaluate 10-year cumulative incidences and relative risk (RR) of developing SIBO in subjects with hypothyroidism (unspecified etiology [HUE]), and a subset with autoimmune thyroiditis, vs propensity score matched control groups. RESULTS: Among REIMAGINE subjects, SIBO prevalence was higher in the hypothyroid group (32.65%) vs controls (15.17%). In the TriNetX analysis, 10-year cumulative incidences of SIBO were higher in HUE (RR = 2.20) and autoimmune thyroiditis (RR = 2.40) subjects vs matched controls. However, these risks appeared to be mitigated both in HUE (RR = 0.33) and autoimmune thyroiditis (RR = 0.78) subjects taking levothyroxine. Analyzing the duodenal microbiome, genus Neisseria was part of the core microbiome in the hypothyroid group (Hypo+/SIBO-, Hypo+/SIBO+) but not in nonhypothyroid subjects (Hypo-/SIBO-, Hypo-/SIBO+). Increased prevalence of Gram-negative coliforms occurred in both SIBO+ groups, but Escherichia/Shigella formed part of the core in nonhypothyroid subjects (Hypo-/SIBO+), whereas Klebsiella species were prevalent in hypothyroid group subjects with SIBO (Hypo+/SIBO+). CONCLUSION: These findings suggest there is an increased risk for development of SIBO in individuals with a history of hypothyroidism that may be ameliorated by treatment, and may involve specific Gram-negative coliforms.
引用
- Wei M, Mehravar S, Leite G, et al. Relationship Between Hypothyroidism, Risk of Small Intestinal Bacterial Overgrowth, and Duodenal Microbiome Alterations. J Clin Endocrinol Metab. 2026. PMID: 40908532. doi:10.1210/clinem/dgaf495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。